Inspire HGNS denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for inspire hgns are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Inspire HGNS as Experimental

Aetna's "experimental or investigational" denial category means the plan has determined — based on its internal clinical policy — that the evidence supporting Inspire hypoglossal nerve stimulation does not yet meet the threshold Aetna uses to classify a technology as proven and non-experimental. Aetna applies a technology assessment process to make these determinations, and its published clinical policy bulletins reflect those assessments. However, Inspire received FDA premarket approval — not merely clearance — and is listed in Aetna's own clinical policy bulletin with specific coverage criteria. This means the denial may reflect a mismatch between the proposed use and the criteria in that bulletin, rather than a true experimental classification.

## Why This Denial Is Appealable

Experimental denials for an FDA-approved device with a published Aetna clinical policy are among the most appealable. First, confirm whether your denial letter cites Aetna's clinical policy bulletin and which specific criterion was not satisfied — that is the precise target for your appeal. If Aetna's own bulletin covers HGNS for your diagnosis under stated criteria, and your clinical record meets those criteria, the "experimental" label cannot stand. If Aetna's bulletin genuinely classifies HGNS as experimental for your specific situation, the appeal should marshal evidence from the relevant medical specialty society (e.g., the applicable sleep medicine or otolaryngology society guideline) demonstrating that the clinical community has accepted this technology.

## Your Federal Appeal Rights

• Internal appeal (ACA §2719): Aetna must have a physician reviewer with expertise in sleep medicine or otolaryngology evaluate an experimental denial for a sleep apnea device.
• External review: Experimental/investigational denials are expressly subject to independent external review under the ACA. The external reviewer applies an objective clinical evidence standard, not Aetna's internal policy.
• ERISA §503: For self-funded employer plans, request the full clinical rationale and all evidence Aetna relied on in making the experimental determination.
• Expedited review: Available if delay poses health risk.
• Timeline: File external review within four months of the final internal adverse determination.

## Documentation to Gather

1. Aetna's clinical policy bulletin: Obtain and read Aetna's current published policy for hypoglossal nerve stimulation. Identify whether HGNS is covered under stated criteria or classified as experimental, and which specific finding triggered the denial. 2. FDA approval documentation: Reference the FDA premarket approval for Inspire, which is publicly available from the FDA's 510(k)/PMA database. 3. Sleep study records: Full polysomnography or home sleep test results, interpreted by a sleep medicine specialist. 4. CPAP failure documentation: Objective adherence data, clinical notes on intolerance, and any alternative PAP therapy attempts. 5. Specialist support letter: A letter from the implanting surgeon and the referring sleep physician citing the applicable sleep medicine society guidelines and addressing Aetna's specific experimental criteria.

## Criteria-Mapping Structure

For an experimental denial, your mapping table must address Aetna's evidence standard directly. Left column: each criterion from Aetna's clinical policy bulletin, including any evidence-level requirement. Right column: the clinical record entry, FDA documentation, or guideline citation that satisfies or rebuts each criterion. If the denial is based on a coverage exclusion for experimental procedures, include a section arguing that HGNS — with its FDA approval and inclusion in specialty society guidelines — does not meet the definition of experimental as defined in the plan documents.